30 participants
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-07-27
- Start Date:
- 2021-10-01
- Completion:
- 2024-05-01
Conditions
- Breast Cancer
Interventions
- DRUG
No Results Yet